Cooley Advises MyoKardia on Collaboration with Sanofi

Palo Alto – September 23, 2014 – Cooley LLP announced today that it advised MyoKardia, Inc. on its collaboration with Sanofi S.A. to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases known as cardiomyopathies, the most common forms of heart muscle disease. The collaboration builds upon MyoKardia's pioneering science, which hopes to correct the disruptive effects that disease mutations have on heart muscle function.

The collaboration, representing one of the largest research and development commitments to genetic forms of cardiomyopathy, encompasses three MyoKardia programs. Two of these programs are focused on hypertrophic cardiomyopathy (HCM) and the other is focused on dilated cardiomyopathy (DCM). The collaboration provides up to $200 million in equity investments, milestone payments and research and development services through 2018, of which $45 million has already been received in an upfront licensing fee and an initial equity investment.

The Cooley team advising MyoKardia included partners Robert Jones, Lila Hope and Danielle Naftulin and associates Rena Kaminsky and Rose Standifer.

About Cooley LLP

Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.

Cooley has more than 750 lawyers across 11 offices in the United States and China.

Related Contacts
Robert L. Jones Partner, Palo Alto
Danielle Naftulin Partner, Palo Alto
Lila Hope Partner, Palo Alto
Rena Kaminsky Special Counsel, Palo Alto
Related Practices & Industries

Life Sciences Corporate Partnering & Licensing